Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

93.14 +1.55 (+1.69%)
Streaming Delayed Price Updated: 1:17 PM EST, Dec 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
Why Arcus Biosciences Stock Vaulted Higher in November
Arcus was one of the few winners in the turbulent biotech space last month. 
Via The Motley Fool
Is Gilead Sciences Stock a Buy Now?
Gilead Sciences is facing multiple headwinds, but there may be hope for the biotech company. 
Via The Motley Fool
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
Gilead Recalls Two Lots Of Remdesivir Due To Presence Of Glass Particulates
Gilead Sciences Inc (NASDAQ: GILD) has issued a nationwide recall of two lots of its COVID-19 treatment drug Remdesivir because of the presence of glass... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
December SPAC Merger Calendar: Upcoming Votes, Stocks To Watch
The month of December shows an increasing number of SPAC deal votes. SPAC merger votes can act as a catalyst, as the votes complete the last step in the merger process and change... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX: 
Via Benzinga
Got $1,000? Check Out These 3 Top Biotech Stocks
Two big biotechs and one smaller one that could be winners over the long term. 
Via The Motley Fool
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
Smaller companies are working on next-generation approaches to Covid treatment. 
Via Investor's Business Daily
Why Are NRx Pharma's Shares Soaring Premarket?
NRx Pharmaceuticals (NASDAQ: NRXP) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's... 
Via Benzinga
3 Dividend Stocks That Are Dirt Cheap Right Now
If you want dividend growth, dividend safety, and an undervalued stock, these three fit the bill. 
Via The Motley Fool
A Look Into Gilead Sciences Debt
Shares of Gilead Sciences (NASDAQ:GILD) fell by 1.76% in the past three months. Before we understand the importance of debt, let us look at how much debt Gilead Sciences... 
Via Benzinga
Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial
Gilead Sciences Inc (NASDAQ: GILD) and Merck & Co Inc (NYSE: MRK) have temporarily paused enrollment in the Phase 2 study evaluating the combination... 
Via Benzinga
Gilead's Trodelvy Approved In Europe For Aggressive Form Of Breast Cancer
The European Commission has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan) as monotherapy for triple-negative breast cancer (... 
Via Benzinga
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In... 
Via Benzinga
Exposures COVID-19 Product Safety
Next Week Trading Opportunities - GILD, ETSY, FCEL, PLUG, SNOW, AAPL
With the assistance of AI we can identify patterns, trends, and buy/sell signals. Here are the prospects in the coming week for these six stocks. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Cancer Stock on Buyout Watch in 2022
Cardiff Oncology is a prime takeover target heading into 2022. 
Via The Motley Fool
Exposures COVID-19
Dividend Initiators: A Fertile Ground For Research
Only a company with a certain type of business can afford to grow dividends over a full business cycle. 
Via Talk Markets
Gilead Files US Application For Bulevirtide In Severe Form Of Viral Hepatitis
Gilead Sciences Inc (NASDAQ: GILD) has submitted a marketing application to FDA for bulevirtide for injection (2 mg) for chronic hepatitis delta virus (HDV)... 
Via Benzinga
Exposures Product Safety
Arcus Stock Rockets To Record As Gilead Unexpectedly Opts Into Cancer Drugs
Gilead opted into three programs from a small biotech company, sending shares flying. 
Via Investor's Business Daily
Why Are Arcus Biosciences Shares Trading Higher Today?
Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT... 
Via Benzinga
Why Arcus Biosciences Stock Is On Fire Today
Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs. 
Via The Motley Fool
2 High-Yield Dividend Stocks That Can Safeguard Your Portfolio Against a Market Crash
AbbVie and Gilead Sciences are two top high-yield stocks that could save your portfolio in the event of a marketwide downturn. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
On Target: This Company Says It Delivers Drugs Exactly How You Need Them
Photo by Anna Shvets from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &... 
Via Benzinga
Top 5 Stocks To Buy In November 2021
High-quality dividend growth stocks are some of the very best stocks in the whole world. They represent equity in world-class businesses that pay reliable, rising dividends. 
Via Talk Markets
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see... 
Via Talk Markets
Best and Worst Performers Since the COVID Crash Low
The major indices have consistently been hitting new record highs over the past few days with the S&P 500 having now more than doubled off the COVID Crash low on March 23, 2020. 
Via Talk Markets
Topics Stocks
Exposures US Equities
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.